German CLL Study Group

0:49
Overview of the CLL2-BIG trial of ibrutinib and obinutuzumab
Julia von Tresckow
1:08
Can concepts from CLL be applied to other liquid and solid tumors?
Paolo Ghia
1:00
Why is personalized medicine important for CLL?
Petra Langerbeins
1:08
The impact of genetic testing on treatment selection in CLL
Anna Schuh
1:38
What are the economics of treating CLL?
John Gribben
1:14
Prognostic markers for CLL – how do they help determine who gets which treatment?
Petra Langerbeins
2:08
How does an understanding of the microenvironment aid research in CLL?
Paolo Ghia
1:02
How to explain the ‘watch-and-wait’ period to a CLL patient?
Petra Langerbeins
1:15
The role of transplant in CLL and Richter’s transformation today
Stephan Stilgenbauer
1:58
Whole genome sequencing in CLL: challenges and benefits
Anna Schuh
2:32
The importance of collaboration across fields and institutions
Dan Landau
2:23
Key considerations for mutation detection in CLL
Anna Schuh
2:10
Overview of CLL12 trial of ibrutinib aiming to delay chemoimmunotherapy
Petra Langerbeins
2:02
Current research at Weill Cornell and the New York Genome Center
Dan Landau
1:07
Where are we with precision medicine for CLL?
John Gribben
2:09
Overview of the CLL13 trial: replacing chemotherapy with venetoclax-containing regimens
Julia von Tresckow
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals